Head-to-head · free
Merck vs NanoViricides, Inc.
MRK vs NNVC — return on capital, cash generation, margins and balance sheet side by side.
MRK
2 / 2
measures where MRK leads
NNVC
0 / 2
measures where NNVC leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MRK · FY2025 | NNVC · FY2026 |
|---|---|---|
| Revenue | $65.0B | — |
| Net income | $18.3B | (8.2M) |
| Revenue growth (yearly, multi-year) | 7.5% | — |
| Free cash flow | $12.4B | (7.8M) |
| Free cash flow margin | 19.0% | — |
| Net cash / (debt) | — | — |
| ROIC | 19.0% | — |
| Return on equity | 36.9% | — |
| Gross margin | 74.8% | — |
| Operating margin | 34.0% | — |
| Net debt / EBITDA | 1.29x | — |
Figures are as reported by each company; latest fiscal year shown.
Where Merck's cash went (FY2025)
- Capital spending
- $4.1B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where NanoViricides, Inc.'s cash went (FY2026)
- Capital spending
- $84317
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free